STRO-003 / Sutro Biopharma, Ipsen - LARVOL DELTA

STRO-003: Protection of patents in US, Taiwan and PCT countries until 2043 (Sutro Biopharma) - Annual Report 2023

Patent • Oncology • Solid Tumor

Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones (GlobeNewswire) - "STRO-002:...Enrollment of REFRαME-P1, a registration-enabling trial for pediatric patients with CBF/GLIS AML, is expected to be initiated in the second half of 2024....Additional Pipeline Development and Collaboration Updates: (i) Sutro plans to submit an IND for STRO-003, a ROR1-targeting ADC, in 2024; (ii) Sutro plans to submit an IND for STRO-004, a tissue factor-targeting ADC, in 2025."

IND • New trial • Acute Myelogenous Leukemia • Solid Tumor

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors (GlobeNewswire) - "Ipsen...and Sutro Biopharma...announced an exclusive global licensing agreement for STRO-003. STRO-003, an antibody-drug conjugate (ADC) in the final stages of pre-clinical development, targets the ROR1 tumor antigen which is known to be overexpressed in many different cancer types including solid tumors and hematological malignancies. The agreement gives Ipsen exclusive worldwide rights to develop and commercialize STRO-003 and will be the first ADC candidate joining Ipsen’s expanding portfolio....Under the terms of the agreement, Ipsen will assume responsibility for Phase I preparation activities, including submission of the Investigational New Drug (IND) application, and all subsequent clinical-development activities and global commercialization activities. Sutro Biopharma is eligible to receive up to $900m in potential upfront, development, regulatory and commercial milestone payments..."

Licensing / partnership • Hematological Malignancies • Solid Tumor

Preclinical Development of STRO-003, a ROR1 Targeting Antibody-Drug Conjugate For Treatment of Hematologic & Solid Cancers (ADC-USA 2023) - "Outlining the discovery and development of a novel ROR1 ADC using a newly designed β-Glu Exatecan linker payload; Providing an overview of the preclinical characterization of STRO-003 anti-tumor efficacy across xenograft and PDX tumor models; Highlighting the pharmacokinetics and attractive safety profile of STRO-003 in non-human primates"

Preclinical • Hematological Malignancies • Oncology • Solid Tumor • ROR1

Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference (GlobeNewswire) - "Sutro Biopharma, Inc...today announced that the company will have five presentations and one poster at the 14th Annual World ADC Conference, taking place in San Diego, October 16-19, 2023."

Clinical data • Preclinical • Hematological Malignancies • Oncology • Solid Tumor

Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones (GlobeNewswire) - "Additional Pipeline Development: STRO-003, a ROR1-targeting ADC and STRO-004, a tissue factor-targeting ADC have INDs planned for Q1 2024 and Q1 2025, respectively."

IND • Oncology • Solid Tumor

Discovery of STRO-003, a Novel ROR1 Targeting ADC Using Cell Free Protein Synthesis and Site-Specific Conjugation Technologies (PEGS 2023) - No abstract available

ROR1

The anti-ROR1 ADC STRO-003 demonstrates immune-modulating properties that may enhance checkpoint blockade (AACR 2023) - "Follow-up vaccination studies were performed to further explore the significance of STRO-003-induced ICD and protective immunity in vivo. These results demonstrate that tumor cells pre-treated with STRO-003 or SC3386 undergo potent immunogenic cell damage which can, in turn, mount protective immunity in vivo."

Checkpoint block • Checkpoint inhibition • IO biomarker • Breast Cancer • Hematological Malignancies • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CALR • HMGB1 • ROR1 • TOP1

Sutro Biopharma Presents Preclinical Data for its ROR1 Targeting Antibody Drug Conjugate STRO-003 at the AACR Annual Meeting 2023 (GlobeNewswire) - "Sutro Biopharma...announced expanded preclinical data for STRO-003, its ROR1 targeting ADC, presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, being held in Orlando, Florida from April 14-19, 2023."

Preclinical • Oncology • Solid Tumor

Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones (GlobeNewswire) - "STRO-003 has demonstrated in NSCLC and breast cancer patient-derived xenograft models strong cell-killing activity in low and heterogeneous expressing tumors. STRO-003 has exhibited promising tolerability in preclinical studies involving rodents and non-human primates, potentially reducing lung toxicity, a concern that is commonly associated with TOPO-1 class payload ADCs. Preparations are underway for IND enabling studies for STRO-003, which we expect will be completed in the first quarter of 2024."

IND • Preclinical • Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer

STRO-003, novel ROR1-targeted ADC with potent activity in breast and lung cancer models (Bioworld) - "Researchers from Sutro Biopharma Inc. presented the discovery and preclinical characterization of a novel receptor tyrosine kinase-like orphan receptor 1 (ROR1)-targeted antibody-drug conjugate (ADC), STRO-003, being developed for the treatment of cancer."

Preclinical • Breast Cancer • Lung Cancer • Oncology • Solid Tumor

STRO-003 is a novel ROR1-targeted ADC for breast and lung cancer (SITC 2022) - "Conclusions Our data suggests that STRO-003 is a promising clinical candidate for solid tumor indications and we have initiated IND-enabling studies. Ethics Approval All in vivo procedures were conducted in compliance with the guidelines of the Institutional Animal Care and Use Committee (IACUC) at Sutro Biopharma or commissioned contract research organization (CRO)."

Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CTSS • ROR1

Sutro Biopharma Reports Second Quarter 2022 Financial Results, Business Highlights and Anticipated Milestones (GlobeNewswire) - "Additional Pipeline Programs: A Sutro Research Forum highlighted STRO-003 and its emerging research portfolio....Patient-derived xenograft models (PDX) have shown potent cell killing by STRO-003 in low antigen expressing tumors; and STRO-003 has shown encouraging tolerability in preclinical rodent and non-human primate studies."

Preclinical • Oncology

Sutro Biopharma Reports Second Quarter 2021 Financial Results, Business Highlights and Anticipated Second Half 2021 Milestones (PRNewswire) - “STRO-003: Preclinical development is underway and a product candidate is expected to be unveiled in the second half of 2021.”

New trial • Oncology